SCHEDULE 13G/A: Affinity Healthcare Fund Discloses 2.89% Passive Stake in Inozyme Pharma
Beneficial Ownership Statement
Affinity Healthcare Fund, LP and its investment manager, Affinity Asset Advisors, LLC, have filed an amended Schedule 13G disclosing a passive beneficial ownership of 2.89% in Inozyme Pharma, Inc.
Summary
- Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC have filed an Amendment No. 1 to Schedule 13G regarding their ownership in Inozyme Pharma, Inc.
- The filing indicates that Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC collectively beneficially own 1,867,710 shares of Inozyme Pharma, Inc.'s Common Stock.
- This ownership represents 2.89% of the outstanding shares of Common Stock of Inozyme Pharma, Inc.
- The percentage is based on 64,561,824 shares of Common Stock outstanding as of May 7, 2025, as reported in Inozyme Pharma's Quarterly Report on Form 10-Q filed on May 14, 2025.
- Both reporting persons, Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC, share voting and dispositive power over all 1,867,710 shares.
- Affinity Asset Advisors, LLC acts as the investment manager for Affinity Healthcare Fund, LP.
- The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of ownership, containing no positive or negative operational news about the issuer. The sentiment is neutral as it simply reports a passive investment stake.
Industry Context
This filing is a standard disclosure of passive ownership by an investment fund in a publicly traded company, common within the financial industry for transparency regarding significant holdings. It does not provide specific insights into Inozyme Pharma's operational performance or industry trends beyond the fact of investment.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant, albeit passive, institutional ownership stake in the company.
Key Dates
| Date | Description |
|---|---|
| 05/07/2025 | Date as of which 64,561,824 shares of Common Stock of the Issuer were outstanding, as reported in the Issuer's Form 10-Q. |
| 05/14/2025 | Date Inozyme Pharma, Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 05/20/2025 | Date of event which requires the filing of this Schedule 13G statement. |
| 05/30/2025 | Date the Schedule 13G statement was signed by Andrew Weinstein on behalf of both reporting persons. |
Keywords
Inozyme Pharma, Affinity Healthcare Fund, Affinity Asset Advisors, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Disclosure, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.